US 11,702,404 B2
GLP-1R modulating compounds
Stephen E. Ammann, Redwood City, CA (US); Gediminas J. Brizgys, San Carlos, CA (US); James S. Cassidy, Foster City, CA (US); Elbert Chin, San Mateo, CA (US); Chienhung Chou, Dublin, CA (US); Jeromy J. Cottell, Redwood City, CA (US); Michael Graupe, Pacifica, CA (US); Chao-I Hung, Foster City, CA (US); Kavoos Kolahdouzan, San Francisco, CA (US); Scott D. Schroeder, Union City, CA (US); Nathan D. Shapiro, Belmont, CA (US); Daniel G. Shore, Redwood City, CA (US); Suzanne M. Szewczyk, San Mateo, CA (US); James G. Taylor, Burlingame, CA (US); Rhiannon Thomas-Tran, San Jose, CA (US); Nathan E. Wright, Foster City, CA (US); Zheng-Yu Yang, Palo Alto, CA (US); and Sheila M. Zipfel, San Mateo, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Oct. 22, 2020, as Appl. No. 17/77,729.
Claims priority of provisional application 63/028,187, filed on May 21, 2020.
Claims priority of provisional application 62/926,270, filed on Oct. 25, 2019.
Prior Publication US 2021/0171499 A1, Jun. 10, 2021
Int. Cl. C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01); C07D 235/16 (2006.01); C07D 403/06 (2006.01); C07D 493/08 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 45/06 (2013.01); C07D 235/16 (2013.01); C07D 401/10 (2013.01); C07D 403/06 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 493/08 (2013.01)] 3 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry